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We intend to submit our manuscript, an original article, entitled Endoscopic palliation of 
malignant biliary strictures: A single center experience, to the Portuguese Journal of 
Gastroenterology. Our study assessed the outcomes of ERCP guided biliary drainage on the 
palliative care of patients with malignant biliary obstructions treated at Centro Hospitalar 
Tâmega e Sousa, E.P.E., and identified patient and tumor related factors with significant impact 
on patients’ survival. We believe our work is relevant for the readership of this journal, since it 
provides a detailed characterization of hard and surrogate outcomes of an extensively used 
Gastroenterology technique on a specific population. This manuscript has not been published 
and is not under consideration for publication in any other journal. All authors approved the 
manuscript and its submission to this journal, and have no conflicts of interest. 
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ABSTRACT AND KEYWORDS 27 
Background and Aims: Malignant biliary strictures (MBS) are generally associated with 28 
advanced neoplasms at the time of diagnosis and with a poor prognosis. In most cases, the only 29 
therapeutic option is palliative care. Endoscopic retrograde cholangiopancreatography (ERCP) 30 
guided biliary drainage is the standard of care for these patients. The aim of this study was to 31 
evaluate the outcomes of this technique on a population of patients with unresectable or 32 
inoperable MBS and to assess the impact of certain factors on patients’ survival. 33 
Methods: A retrospective analysis of patients with an unresectable/inoperable MBS who 34 
attempted ERCP guided biliary drainage at Centro Hospitalar Tâmega e Sousa from January 1st, 35 
2013 to September 30th, 2016 was performed. The outcomes evaluated included technical 36 
success, functional success, early and late complications, stent patency and patient survival. A 37 
multivariate analysis was performed to identify the variables associated with survival. 38 
Results: Seventy-seven patients were included in the study. Mean patient age was 76.7 years. 39 
The most frequent cause of MBS was pancreatic carcinoma (48.1%), followed by 40 
cholangiocarcinoma (31.2%). Technical success of the first ERCP guided biliary drainage was 41 
66.2%. Median total bilirubin relative decrease was 71.1%. Early and late complications rates 42 
were 26% and 31.8%, respectively. Median stent patency was 68 days and median patient 43 
survival after biliary drainage was 98 days. In multivariate analysis, age at diagnosis, etiology of 44 
the stricture, pretreatment total bilirubin and leukocyte levels were significantly associated with 45 
survival. 46 
Conclusions: ERCP guided biliary drainage outcomes depend on patient and tumor 47 
characteristics, as well as on institutional volume and experience. Patient survival is related to 48 
age at diagnosis, etiology of the stricture and pretreatment total bilirubin and leukocyte levels. 49 
Key messages: ERCP guided biliary drainage is the cornerstone of palliative care for most 50 
patients with MBS. Patient and tumor characteristics influence patients’ prognosis. 51 
Keywords: malignant biliary strictures; palliation; ERCP; biliary drainage.  52 
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RESUMO E PALAVRAS-CHAVE 53 
Introdução e Objetivos: As obstruções biliares por patologia maligna (OBPM) estão geralmente 54 
associadas a neoplasias avançadas e a um mau prognóstico. A maioria tem indicação para 55 
tratamento paliativo, sendo a drenagem biliar por colangiopancreatografia retrógrada 56 
endoscópica (CPRE) a abordagem-padrão nestes casos. O objetivo deste estudo foi avaliar os 57 
resultados desta técnica em pacientes com OBPM irressecável/inoperável e avaliar o impacto 58 
de alguns fatores na sobrevida.  59 
Métodos: Realizou-se uma análise retrospetiva dos doentes com OBPM irressecável/inoperável 60 
submetidos a drenagem biliar por CPRE no Centro Hospitalar Tâmega e Sousa entre 01-01-2013 61 
e 30-09-2016. Os resultados avaliados incluíram: sucesso técnico, sucesso funcional, 62 
complicações precoces e tardias, patência da prótese e sobrevida. Realizou-se uma análise 63 
multivariada para identificar as variáveis com impacto na sobrevida dos doentes. 64 
Resultados: Foram incluídos neste estudo 77 doentes com uma idade média de 76,7 anos. A 65 
causa mais frequente de OBPM foi o carcinoma pancreático (48,1%), seguido do 66 
colangiocarcinoma (31,2%). O sucesso técnico do primeiro procedimento foi de 66,2%. A 67 
mediana da diminuição da bilirrubina total foi de 71,1%. As taxas de complicações precoces e 68 
tardias foram de 26% e 31,8%, respetivamente. As medianas da patência da prótese e da 69 
sobrevida após a drenagem biliar foram de 68 e 98 dias, respetivamente. Na análise 70 
multivariada, a idade, a etiologia da obstrução e os níveis pré-tratamento de bilirrubina total e 71 
de leucócitos associaram-se significativamente com a sobrevida. 72 
Conclusões: Os resultados da drenagem biliar por CPRE estão relacionados com as 73 
características do doente e do tumor, bem como com o volume e a experiência da instituição. A 74 
sobrevida dos doentes depende da idade, da etiologia da OBPM e dos níveis pré-tratamento de 75 
bilirrubina total e de leucócitos. 76 
Mensagens-chave: A drenagem biliar por CPRE é um fulcral no tratamento paliativo das OBPM. 77 
As características do doente e do tumor influenciam o prognóstico. 78 
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Palavras-chave: obstruções biliares por patologia maligna; tratamento paliativo; CPRE; 79 
drenagem biliar.  80 
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INTRODUCTION 81 
Malignant biliary strictures (MBS) are rare, but their incidence seems to be increasing with 82 
time and they are generally associated with a poor prognosis [1-3]. They are caused by a variety 83 
of neoplasms and can occur as the initial manifestation of the disease or appear with its 84 
progression [1]. The most common causes of MBS are pancreatic carcinomas and 85 
cholangiocarcinomas [1, 2, 4]. Less frequent causes of MBS include ampullary carcinomas, 86 
duodenal primary carcinomas, neuroendocrine pancreatic tumors, gallbladder carcinomas, 87 
primary or secondary liver neoplasms and hilar obstructions by porta hepatis adenopathies 88 
secondary to locoregional metastases or lymphomas [1, 2, 4]. Biliary obstructions occur in 70-89 
90% of patients with neoplasms involving the biliary tree [2] and 75% of cephalopancreatic 90 
ductal adenocarcinomas manifest with jaundice [5]. 91 
MBS are classified, according to their location, in intra- and extra-hepatic [6, 7]. Intra-92 
hepatic focal malignant obstructions are rare and frequently found incidentally [7]. Since most 93 
of these cases do not have indication for biliary drainage, they will not be included in this study. 94 
Extra-hepatic (hilar or distal) strictures are the most common causes of MBS [7], and 95 
usually manifest with nonspecific symptoms, like jaundice, pruritus, anorexia and malaise, which 96 
can also be present in benign conditions [1, 2]. Cholestasis is associated with debilitating 97 
symptoms and can interfere with cellular immunity and cause immunosuppression, facilitating 98 
tumor growth and metastatic spread [1, 5]. It also predisposes patients to infection, systemic 99 
inflammatory response syndrome and sepsis [1, 5]. Furthermore, cholestasis reduces the bile 100 
flow to the enteric system, impairing fat soluble vitamins absorption and predisposing the 101 
patient to the associated complications [1]. 102 
Hilar MBS are less frequent than the distal causes, and include cholangiocarcinomas and 103 
neoplasms involving the hepatic confluence by direct extension from the gallbladder, liver or 104 
metastatic nodal disease [4, 6]. 105 
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Contrast enhanced computed tomography (CT) and/or magnetic resonance 106 
cholangiopancreatography (MRCP) are necessary for diagnosis, adequate assessment of tumor 107 
relations to the biliary and vascular anatomy and for treatment planning [4]. The role of 108 
pathological analysis on determining the etiology of the obstruction is limited by its low 109 
sensitivity [8, 9]. 110 
The poor prognosis associated with MBS is secondary to the locoregional invasiveness of 111 
these neoplasms, high rate of distant metastases, late symptomatology onset and higher 112 
incidence in the elderly, which makes them frequently unresectable and/or inoperable at the 113 
time of diagnosis [3, 8]. Although in certain cases downstaging is possible, with neoadjuvant 114 
chemo- and/or radiotherapy, making some tumors resectable, in most cases the only 115 
therapeutic option is palliative care [1, 3]. 116 
Biliary drainage is the cornerstone of treatment of such obstructions, as it provides 117 
symptomatic relief and quality of life improvements, avoids some of the complications 118 
associated with cholestasis and jaundice, prolongs survival, and, in some cases, enables 119 
“bridging” to curative surgical treatment [1, 10-12]. Biliary drainage can be achieved by three 120 
distinct approaches: bilioenteric anastomosis (a General Surgery procedure), percutaneous 121 
biliary drainage (an Interventional Radiology procedure) and endoscopic biliary drainage (by 122 
endoscopic retrograde cholangiopancreatography (ERCP) or, more recently, by endoscopic 123 
ultrasound, both Gastroenterology procedures) [2, 13]. 124 
In the past, biliary drainage was confined to surgical bypass, but recently minimally 125 
invasive techniques have assumed an increasingly important role [4, 12]. Surgical bypass, when 126 
feasible, is associated with low recurrent jaundice rates (2-5%) but with higher morbi-mortality 127 
rates compared to minimally invasive techniques, and is more expensive [2, 4, 14]. ERCP guided 128 
biliary drainage is the standard of care and is preferred to percutaneous biliary drainage for most 129 
extra-hepatic malignant strictures, since it is less invasive and provides similar results [1, 11]. For 130 
hilar lesions, namely type II-IV hilar MBS, percutaneous biliary drainage seems to provide a 131 
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higher success rate and less infectious complications [1, 11]. Furthermore, minimally invasive 132 
biliary drainage procedures allow evaluation of the biliary tree anatomy and tissue sample 133 
collection for pathological analysis [15]. 134 
ERCP stents are in constant technological evolution and may be divided into two major 135 
categories: plastic stents (PS) and self-expandable metallic stents (SEMS) [1-4, 6]. The selection 136 
between these two types of stents depends on diagnostic certainty, expected survival and cost-137 
efficacy relation, and must be personalized according to the characteristics of each patient [1, 138 
16, 17]. 139 
The aim of our retrospective analysis was to evaluate ERCP guided biliary drainage 140 
outcomes, namely technical and functional success rates, early and late complications, stent 141 
patency and survival on patients with unresectable or inoperable MBS admitted to Centro 142 
Hospitalar Tâmega e Sousa (CHTS) between January 1st, 2013 and September 30th, 2016. 143 
Additionally, we evaluated the impact of certain demographic, clinical, biochemical and 144 
treatment-related factors on patient survival.  145 
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MATERIALS AND METHODS 146 
A retrospective analysis of a prospective cohort of all consecutive patients with an 147 
unresectable or inoperable MBS that attempted palliative ERCP guided biliary drainage at CHTS 148 
from January 1st, 2013 to September 30th, 2016 was performed. The study was approved by the 149 
Hospital’s Ethical Committee and Administration Board. 150 
All patients, 18 years or older, with the diagnosis of a MBS with indication for palliative 151 
biliary drainage (based on disease extent or patients’ medical fitness), having undergone the 152 
first ERCP guided biliary drainage attempt from January 1st, 2013 to September 30th, 2016 at 153 
CHTS were included in the study. Patients undergoing ERCP with stent placement as a “bridging” 154 
technique for a future therapy with a potentially curative intent and patients undergoing biliary 155 
drainage by other techniques, namely surgical, percutaneous or endoscopic ultrasonography 156 
guided, were excluded from the study.  157 
Diagnosis was based on clinical, laboratory and imaging results (ultrasonography, CT, 158 
MRCP and/or ERCP) and, when possible, pathological analysis of a biopsy or exfoliative cytology 159 
specimen.  160 
ERCP was performed by one of the authors, an experienced endoscopist, using a 161 
therapeutic duodenoscope. During the procedure, patients were under sedation, monitored 162 
and supervised by an anesthesiologist, in the prone position. After performing a cholangiogram, 163 
a guidewire was passed through the stricture and a biliary stent was placed using a delivery 164 
system. Both PS and SEMS were used. Sphincterotomy was performed when necessary to 165 
facilitate more complex stenting procedures.  166 
Data was collected from the ERCP hospital registry and from the patients’ medical records 167 
from January 1st, 2013 until the patients’ death or until the end of the follow-up period 168 
(November 30th, 2016). Patients’ demographic information and American Society of 169 
Anesthesiologists (ASA) physical status classification were registered. Dates of malignancy 170 
diagnosis, biliary drainage and death were recorded. Imaging techniques results, pathological 171 
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reports, ERCP reports, hospital notes and blood laboratory analysis, before and after stent 172 
placement, were reviewed. 173 
The first ERCP with therapeutic intent performed in each patient was evaluated. If it failed 174 
to correctly place a stent and the procedure was later repeated, we also collected data from 175 
subsequent ERCP procedures (until effective stent placement), in order to evaluate the global 176 
efficacy of ERCP in this context. 177 
A descriptive statistical characterization of the studied population was performed. The 178 
biliary drainage outcomes assessed were: technical success (successful stent placement through 179 
the stricture and flow of bile or contrast medium through the stent), functional success 180 
(decrease in total bilirubin levels), early (≤30 days) and late (>30 days) complications rates, 181 
median overall stent patency (time between successful biliary drainage and stent occlusion, 182 
stent prophylactic substitution, patients’ death or end of follow-up period) and median stent 183 
patency until occlusion, and median survival (time between successful biliary drainage and 184 
patients’ death or end of follow-up period). Thirty-day mortality rate was calculated. Overall 185 
survival was evaluated and registered using a Kaplan-Meier curve. A multivariate analysis using 186 
Cox regression was performed in order to identify factors influencing patients’ survival. The 187 
studied variables included: age at diagnosis, sex, ASA classification, established diagnosis, 188 
pretreatment blood analysis levels (total bilirubin, hemoglobin, leukocytes, C-reactive protein 189 
(CRP), serum albumin, International Normalized Ratio (INR) and serum creatinine levels) and 190 
chemotherapy. A p-value of <0.05 was considered significant and 95% confidence intervals were 191 
used. The statistical analysis was performed using Stata (version 14.0 for MacOS) and SPSS 192 
(version 24.0 for MacOS).  193 
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RESULTS 194 
Seventy-seven patients were considered eligible for the study, and follow-up data until 195 
death or until the end of the data collection period (November 30th, 2016) was obtained for all. 196 
The characteristics of the study population are presented in Table 1. Mean age at diagnosis was 197 
76.7 years and 51.9% of the patients were male. 198 
The most frequent cause of MBS was pancreatic carcinoma (48.1% of patients), followed 199 
by cholangiocarcinoma (31.2%). It was not possible to determine the origin of the malignancy in 200 
3 patients (3.9%). Pathological diagnostic confirmation was obtained in only 20 patients (26%). 201 
During the period between January 1st, 2013 and September 30th, 2016 (45 months) 83 202 
ERCPs for MBS were performed. PS were used in 50 patients (89.3%) and SEMS in 6 (10.7%). 59 203 
patients (76.6%) underwent sphincterotomy to facilitate the biliary tree cannulation. 204 
Table 2 displays the ERCP guided biliary drainage outcomes. The first ERCP guided biliary 205 
drainage was technically successful in 51 of the 77 patients (66.2%).  A second attempt was 206 
performed in 6 patients with technical success in 5 (83.3%).  207 
Functional success was evaluated by the decrease in total bilirubin levels. Median 208 
pretreatment total bilirubin level was 17.9mg/dL and median post treatment total bilirubin level 209 
was 4.2mg/dL. The median absolute decrease was 11.3mg/dL and the median decrease rate was 210 
71.1%. 211 
Early complications occurred in 20 patients (26%) and included cholangitis (90%), 212 
pancreatitis (5%) and stent dysfunction (5%). Late complications occurred in 14 patients (31.8%) 213 
and included stent dysfunction (57.1%) and cholangitis (42.9%).  214 
Stents were functional at the end of the data collection period in 7 of the 56 patients in 215 
whom biliary drainage was technically successful (median follow-up time: 447 days). Planned 216 
stent substitution was performed in the absence of stent dysfunction in 6 patients (12.2%), 217 
occlusion occurred in 10 patients (20.4%) and 33 patients (67.3%) died before stent dysfunction 218 
or substitution. 219 
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Median overall stent patency was 68 days and median patency until occlusion was 57.5 220 
days. Kaplan-Meier cumulative patency analysis was performed (Figure 1). Patency cumulative 221 
rates were 71.4%, 40.4%, 23.1% and 9.2% at 1, 3, 6 and 12 months, respectively. 222 
There were no immediate deaths associated with the procedure. Thirty-day mortality rate 223 
after the first ERCP was 20.8%. At the end of the follow-up period only 7 patients (9.1%) were 224 
alive. A Kaplan-Meier cumulative survival analysis was performed, as shown in Figure 2. Median 225 
survival time after successful biliary drainage was 98 days. The curve shows that the survival 226 
rates after the first ERCP were 76.8%, 51.3%, 25.7% and 11.5% at 1, 3, 6 and 12 months, 227 
respectively. 228 
Multivariate analysis (Table 3) identified older age at diagnosis (Hazard Ratio (HR)=1.11, 229 
p=0.009), diagnosis of hepatic metastasis from non-hepatobiliopancreatic (HBP) primary 230 
neoplasms (HR=50.68, p=0.007), high pretreatment total bilirubin levels (HR=1.07, p=0.014) and 231 
high pretreatment leukocyte levels (HR=1.29, p=0.028) as negative predictors of survival.  232 
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DISCUSSION AND CONCLUSIONS 233 
Seventy-seven patients were included in the study and 40 of them were males (51.9%), 234 
which is similar to the results published by other studies [5, 18, 19]. On the other hand, the mean 235 
age of our population was 76.7 years, higher than that reported in other studies [12, 18-21], 236 
which may have had a negative effect on some outcomes evaluated in our study, namely 237 
survival. It also highlights the importance of palliative care of patients with MBS: elderly patients 238 
may be unfit for surgery and other aggressive approaches (even in the presence of resectable 239 
tumors) given their frailty, and a palliative approach may be the only viable therapeutic option 240 
in order to improve the patients’ quality of life. However, even though most patients were 241 
elderly, some were as young as 51 years of age. This reflects the aggressiveness of some of the 242 
underlying malignancies and the paucity of clinical signs and symptoms that could allow an early 243 
diagnosis, impeding a curative intent even in young patients. 244 
Patients ASA status was included as an indicator of their physical status. 46.2% of patients 245 
were classified as ASA-2 (mild to moderate systemic disease without functional impairment) and 246 
47.7% as ASA-3 (severe systemic disease with functional impairment). Therefore, even though 247 
ASA status did not influence survival on multivariate analysis, certain characteristics of the 248 
studied population, namely comorbidities and poor underlying physical condition, might have 249 
had a deleterious effect on biliary drainage outcomes and prognosis. 250 
The most common etiology of MBS was pancreatic carcinoma (48.1% of cases), followed 251 
by cholangiocarcinoma (31.2% of cases). Rarer causes included ampullary carcinoma, 252 
gallbladder carcinoma and hepatic metastasis from non-HBP primary neoplasms, resembling the 253 
frequencies reported by other authors [12, 19, 21]. Pathological diagnostic confirmation was 254 
obtained in 26% of patients; in the remainder, diagnosis was based on clinical, imaging and 255 
laboratory results. Similar pathological confirmation rates have been reported by other authors, 256 
reflecting the importance of imaging techniques on establishing diagnosis and treatment 257 
algorithms nowadays [18, 19]. Despite having a limited sensitivity and also the possibility of 258 
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associated morbidity due to the attempts to obtain the specimens, pathological analysis plays 259 
an important role on prognosis determination and treatment planning in some patients [8, 9], 260 
and endoscopists should be encouraged to collect tissue samples whenever possible. Combining 261 
biopsy and exfoliative cytology or performing multiple sample collections by one of these 262 
methods increases the sensitivity of the procedure [9]. New pathological techniques are 263 
currently being developed in order to improve analysis sensitivity and specificity [9]. 264 
Our results revealed an ERCP guided biliary drainage technical success rate of 66.2% on 265 
the first ERCP and of 83.3% on the second attempt, whenever the first failed. Some studies 266 
report higher technical success rates on the first ERCP, but similar rates on the second procedure 267 
[1, 11-13, 17]. According to the literature, the technique can fail for several reasons, such as 268 
difficulties on reaching the papilla, on cannulating the bile ducts or on retrogradly passing the 269 
stenosis, and success rate is influenced by the endoscopist’s experience, volume of procedures 270 
performed in the center, adequate patient sedation and type of neoplasms included in the 271 
study, and is not influenced by the type of stent used [11, 22]. In our institution, more than 200 272 
ERCPs are performed annually by a single endoscopist. The lower technical success rate found 273 
in our study may be related to endoscopist´s experience or institutional volume but also to the 274 
advanced stage of some malignancies, therefore impeding the passage of the duodenoscope 275 
through the duodenum, the papilla or the stricture, and to the heterogeneity of neoplasms 276 
assessed, including hilar cholangiocarcinomas and hepatic metastasis from non-HBP primary 277 
neoplasms, with an associated increase in the technical difficulty of the procedure. 278 
Median pretreatment total bilirubin level was 17.9mg/dL, and patients with a technically 279 
successful ERCP had a median decrease in total bilirubin level of 11.3mg/dL. 43 patients (76.8%) 280 
had a total bilirubin decrease rate superior to 20%, a similar proportion to that obtained by 281 
Abraham and colleagues (78%) [21]. The median decrease rate observed in this series was 282 
71.1%, indicating that most patients have a significant improvement in cholestasis after the 283 
procedure. We also evaluated the percentage of patients with normalization of the total 284 
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bilirubin level (post-treatment bilirubin levels ≤2mg/dL), and verified that it only occurred in 12 285 
patients (21.4%). Weston and colleagues reported a much higher normalization rate (76%) [23]. 286 
However, it must be considered that the post-treatment total bilirubin level was obtained by 287 
retrospectively reviewing patients blood analysis results available on their medical records 288 
(either performed while the patient was still admitted to the hospital or after discharge) and 289 
that it may not reflect the lowest total bilirubin level reached over the post-treatment period, 290 
as would be ideal. According to the available literature, some patient and tumor related factors 291 
seem to decrease the likelihood of functional success, namely high pretreatment bilirubin levels, 292 
INR≥1.5 and the presence of diffuse liver metastases [11]. 293 
In this series, post-ERCP early complications occurred in 26% of patients. The most 294 
frequent early complication was cholangitis, as was expected from the literature review [11, 12, 295 
18, 24]. At our institution, ESGE guidelines are followed, and antibiotic prophylaxis is only 296 
administered to high risk patients or if incomplete biliary drainage is anticipated [11]. However, 297 
broad-spectrum antibiotics are prophylactically administered to all patients in some centers, 298 
which might be responsible for the lower complication rates reported in those centers (5-10%), 299 
with a significantly lower incidence of infection [18, 24]. 300 
  Late complications occurred in 31.8% of patients, and were more frequently observed in 301 
patients with PS (32.5% vs 25.0%), as expected. The most common late complication was stent 302 
dysfunction, followed by cholangitis, as reported by others [11]. Our overall late morbidity rate 303 
reflects the PS morbidity rate, since it was used in 89.3% of patients. The difference in late 304 
complications rates between the two stent types is in accordance with that reported in the 305 
literature [1-4, 11, 12, 17, 18].  306 
Median overall stent patency was 68 days (2.3 months). This variable included patients 307 
who had their stents prophylactically substituted, who died before stent dysfunction and who 308 
had the stent still patent at the end of the follow-up period. It is important to remember that PS 309 
were used in most patients, and that this type of stent is associated with a shorter stent patency 310 
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than SEMS, as indicated in a meta-analysis performed by Moss and colleagues: median PS 311 
patency varied from 2 to 5.5 months and median SEMS patency from 3.7 to 9.1 months [25]. 312 
Median patient survival in our study population, from the first successful biliary drainage, 313 
was 98 days (3.3 months), which is less than that reported in the literature (4-7.4 months) [12, 314 
19]. The shorter survival reported in our series may be related to a relatively older population 315 
group with a poorer physical status in comparison to other similar studies, to the exclusion of 316 
patients with possible indication for a curative intent treatment and to the inclusion of 317 
malignancies with an overall worse prognosis. 318 
In multivariate analysis, four factors were identified as independent negative predictors 319 
of survival: older age at diagnosis, diagnosis of hepatic metastases from non-HBP primary 320 
neoplasms, high pretreatment total bilirubin levels and high pretreatment blood leukocyte 321 
levels. Older age at diagnosis, as previously discussed, is frequently associated with a poorer 322 
functional status, the probable reason for the shortened survival. This correlation has also been 323 
reported by others [5, 26]. Controversially, Weaver and colleagues indicated that an older age 324 
at diagnosis was associated with a prolonged survival, stating that it was possibly because older 325 
people tend to have less aggressive tumors [19]. Such association, to the best of our knowledge, 326 
has not been reported elsewhere. Regarding the etiology of the stricture, our analysis showed 327 
that hepatic metastases from non-HBP primary neoplasms were associated with a poor 328 
prognosis, probably because they reflect an advanced stage of a neoplasm unresponsive to 329 
systemic therapy. Similarly to our findings, hyperbilirubinemia has been reported in the 330 
literature to be negatively associated with survival, probably because cholestasis facilitates 331 
tumor growth and metastatic spread and predisposes patients to a variety of complications [5, 332 
27]. As suggested by our study, high blood leukocyte levels seem to be an independent predictor 333 
of shorter survival, especially in patients with pancreatic carcinomas [28]. Some authors have 334 
described a correlation between the intensity of the systemic inflammatory response and the 335 
aggressiveness of such neoplasms [29]. Several studies have identified a variety of other factors 336 
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significantly affecting survival. Some of these covariates were included in our study but were 337 
not found to be significant predictors of survival (hemoglobin, serum albumin and 338 
chemotherapy), and others were not assessed (clinical stage) [12, 28]. The identification of 339 
survival predictors is very important for prognosis assessment and treatment planning. 340 
However, because study designs and population characteristics are widely variable between 341 
studies, there is no consensus on what factors should be used for prognosis determination. 342 
Our investigation presents some limitations. We studied a small heterogeneous 343 
population group assisted at a single institution, which reduces the probability of finding 344 
statistically significant results and affects the generalizability of the study. The fact that we 345 
included patients older than those enrolled in most of the studies published in the literature 346 
may help to fill a blank space in the prognostic evaluation of the more elderly. In a retrospective 347 
study, like ours, misclassification bias is more likely to occur and data may not be available for 348 
analysis. A careful and organized data collection was performed to minimize these possible error 349 
sources. Selection bias may also have occurred: patients with an initial indication for a 350 
potentially curative treatment attempt were excluded from the study even if their disease was 351 
considered “borderline resectable” on admission; some of these patients may have been later 352 
considered not resectable. This would make them eligible for our study, possibly changing the 353 
baseline characteristics of our population (like age and comorbidities), as well as some of the 354 
outcomes assessed, namely overall survival. 355 
Few studies have focused on palliative biliary drainage, and to our knowledge only one 356 
comparable study has been developed in Portugal, which focused on hilar cholangiocarcinomas 357 
and not on all MBS [18]. Therefore, we consider our study to be of great utility, locally and in 358 
other centers, not only because it reinforces the usefulness of ERCP guided biliary drainage on 359 
the palliative care of MBS, but also because it encourages the development of early diagnosis 360 
approaches and of new algorithms for prognosis prediction, therefore ensuring a more 361 
individualized and cost-effective approach. It also stimulates the development of a prospective 362 
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multicentric study on ERCP guided biliary drainage. This study design would guarantee better 363 
study conditions with a closer follow-up and a more accurate assessment of patient and tumor 364 
characteristics and of primary and secondary outcomes. 365 
Another challenge for the near future is the development of techniques that provide a 366 
sustained symptomatic relief. Endoscopic procedures currently under investigation and showing 367 
promising results include intraductal radiofrequency ablation, photodynamic therapeutics and 368 
intratumoral injection of chemotherapeutic and immunologic agents [5, 6]. These techniques 369 
will probably play and increasingly important role on the palliation of MBS.  370 
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TABLES AND FIGURES LEGENDS 
Table 1 – Characteristics of the studied population. 
SD – standard deviation; ASA – American Society of Anesthesiologists; IQR – 
Interquartile range; CRP – C-Reactive Protein; INR – International Normalized Ratio. 
Table 2 - ERCP guided biliary drainage outcomes. 
ERCP – endoscopic retrograde cholangiopancreatography; IQR – Interquartile range; 
CI – confidence interval. 
Table 3 - Multivariate analysis of possible predictors of survival. 
HR – Hazard Ratio; CI – Confidence Interval; ASA – American Society of 
Anesthesiologists; HBP – hepatobiliopancreatic; INR – International Normalized 
Ratio; CRP – C-Reactive Protein. 
Figure 1 - Kaplan-Meier cumulative stent patency curve showing stent patency after 
successful ERCP guided biliary drainage in patients with unresectable/inoperable 
malignant biliary strictures treated at CHTS from January 1st, 2013 to September 30th, 
2016.  
Figure 2 - Kaplan-Meier cumulative survival curve showing patients’ survival after 
successful ERCP guided biliary drainage in patients with unresectable/inoperable 
malignant biliary strictures treated at CHTS from January 1st, 2013 to September 
30th, 2016. 
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TABLES 
 
Table 1 – Characteristics of the studied population 
Age at diagnosis (years)  
Mean (SD) 76.7 (9.6) 
Range 51-94 
Sex (n (%)) 
Male 40 (51.9) 
Female 37 (48.1) 
ASA classification (n (%)) 
1 0 (0) 
2 30 (46.2) 
3 31 (47.7) 
4 4 (6.2) 
Diagnosis (n (%)) 
Pancreatic carcinoma 37 (48.1) 
Cholangiocarcinoma 24 (31.2) 
Ampullary carcinoma 7 (9.1) 
Gallbladder carcinoma 1 (1.3) 
Hepatic metastasis 5 (6.5) 
Indeterminate malignant obstruction 3 (3.9) 
Anatomopathological confirmation (n (%)) 
Yes 20 (26.0) 
No 57 (74.0) 
Pretreatment blood indices 
Total bilirubin levels (mg/dL) 
Median (IQR) 17.9 (12.3-23.8) 
Hemoglobin levels (g/dL) 
Median (IQR) 11.3 (10.2-12.6) 
Leukocyte levels (103/μL) 
Median (IQR) 7.65 (6.15-9.58) 
CRP levels (mg/L) 
Median (IQR) 32.8 (18.1-74.9) 
Albumin levels (g/dL) 
Median (IQR) 2.7 (2.2-3.2) 
INR levels 
Median (IQR) 1.07 (0.98-1.15) 
Creatinine levels (mg/dL) 
Median (IQR) 0.9 (0.7-1.2) 
Chemotherapy (n (%)) 
Yes 6 (7.8) 
No 71 (92.2) 
SD – standard deviation; ASA – American Society of Anesthesiologists; IQR 
– Interquartile range; CRP – C-Reactive Protein; INR – International 
Normalized Ratio.  
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Table 2 – ERCP guided biliary drainage outcomes 
Technical success rate (n (%)) 
First ERCP 51 (66.2) 
Second ERCP (if first ERCP failed) 5 (83.3) 
Functional success 
Post-treatment total bilirubin levels (mg/dL)  
Median (IQR) 4.2 (2.3-9.0) 
Decrease in total bilirubin levels (mg/dL)  
Median (IQR) 11.3 (4.5-17.0) 
Total bilirubin decrease rate (%)  
Median (IQR) 71.1 (40.3-86.7) 
Normalization of total bilirubin levels (≤2mg/dL) (n (%)) 
Yes 12 (21.4) 
No 44 (78.6) 
Total bilirubin decrease rate >20% (n (%)) 
Yes 43 (76,8) 
No 13 (23,2) 
Complications 
Early complications (n (%))  
Overall incidence 20 (26) 
Cholangitis 18 (90) 
Pancreatitis 1 (5) 
Stent dysfunction 1 (5) 
Late complications (n (%))  
Overall incidence 14 (31.8) 
Stent dysfunction 8 (57.1) 
Cholangitis 6 (42.9) 
By stent type  
Plastic stents 13 (32.5) 
Self-expandable metallic stents 1 (25) 
Stent patency 
End of Patency (n (%))  
Occlusion 10 (17.9) 
Planned substitution 6 (10.7) 
Death 33 (58.9) 
End of follow-up time 7 (12.5) 
Overall patency time (days)  
Median (95% CI) 68.0 (45.6-90.4) 
Patency time until occlusion (days)  
Median (IQR) 57.5 (11.5-135.3) 
Survival 
Median survival (95% CI) (days) 98.0 (60.5-135.5) 
Procedure-associated mortality (n (%)) 0 (0) 
30-day mortality (n (%)) 13 (23.2) 
ERCP – endoscopic retrograde cholangiopancreatography; IQR – 
Interquartile range; CI – confidence interval. 
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Table 3 – Multivariate analysis of possible predictors of survival 
Variables HR 95% CI p-value 
Age at diagnosis 1.11 1.03-1.20 0.009 
Gender (female vs male) 1.38 0.46-4.13 0.561 
ASA Classification   0.216 
ASA-2 Ref   
ASA-3 2.26 0.79-6.52 0.131 
ASA-4 0.65 0.14-3.02 0.582 
Diagnosis   0.039 
Pancreatic carcinoma Ref   
Cholangiocarcinoma 0.77 0.31-1.92 0.571 
Hepatic metastasis from non-
HBP primary neoplasms 
50.68 2.87-895.86 0.007 
Ampullary carcinoma 1.24 0.26-5.93 0.790 
Unknown 1.20 0.28-5.12 0.801 
Pretreatment total bilirubin 1.07 1.01-1.13 0.014 
Pretreatment serum albumin 1.63 0.67-3.98 0.281 
Pretreatment hemoglobin 1.10 0.84-1.44 0.484 
Pretreatment INR 6.12 0.20-185.81 0.297 
Pretreatment blood leukocyte 1.29 1.03-1.62 0.028 
Pretreatment CRP 0.99 0.97-1.01 0.314 
Pretreatment serum creatinine 1.77 0.74-4.21 0.197 
Chemotherapy (no vs yes) 0.70 0.09-5.40 0.729 
  
HR – Hazard Ratio; CI – Confidence Interval; ASA – American Society of 
Anesthesiologists; HBP – hepatobiliopancreatic; INR – International 
Normalized Ratio; CRP – C-Reactive Protein. 





Figure 1 – Kaplan-Meier cumulative stent patency curve showing stent patency after successful 
ERCP guided biliary drainage in patients with unresectable/inoperable malignant biliary 
























Figure 2 – Kaplan-Meier cumulative survival curve showing patients’ survival after successful 
ERCP guided biliary drainage in patients with unresectable/inoperable malignant biliary 
strictures treated at CHTS from January 1st, 2013 to September 30th, 2016. 
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